MA29788B1 - Combinaisons comprenant un inhibiteur des recepteurs vegf - Google Patents

Combinaisons comprenant un inhibiteur des recepteurs vegf

Info

Publication number
MA29788B1
MA29788B1 MA30759A MA30759A MA29788B1 MA 29788 B1 MA29788 B1 MA 29788B1 MA 30759 A MA30759 A MA 30759A MA 30759 A MA30759 A MA 30759A MA 29788 B1 MA29788 B1 MA 29788B1
Authority
MA
Morocco
Prior art keywords
vegf receptor
receptor inhibitor
combinations
composition
relates
Prior art date
Application number
MA30759A
Other languages
English (en)
Inventor
Andreas Billich
Anton Stuetz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518671A external-priority patent/GB0518671D0/en
Priority claimed from GB0518672A external-priority patent/GB0518672D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29788B1 publication Critical patent/MA29788B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

CETTE INVENTION CONCERNE UNE COMPOSITION COMPRENANT UN INHIBITEUR DES RÉCEPTEURS VEGF AINSI QU'UN AGENT FACILITANT LA PÉNÉTRATION. L'INVENTION CONCERNE ÉGALEMENT DES MÉTHODES PERMETTANT D'UTILISER UNE TELLE COMPOSITION.
MA30759A 2005-09-13 2008-03-17 Combinaisons comprenant un inhibiteur des recepteurs vegf MA29788B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518671A GB0518671D0 (en) 2005-09-13 2005-09-13 Organic compounds
GB0518672A GB0518672D0 (en) 2005-09-13 2005-09-13 Organic compounds

Publications (1)

Publication Number Publication Date
MA29788B1 true MA29788B1 (fr) 2008-09-01

Family

ID=37663150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30759A MA29788B1 (fr) 2005-09-13 2008-03-17 Combinaisons comprenant un inhibiteur des recepteurs vegf

Country Status (23)

Country Link
US (2) US20080306058A1 (fr)
EP (1) EP1945217B1 (fr)
JP (1) JP2009507871A (fr)
KR (1) KR20080058376A (fr)
AR (1) AR056194A1 (fr)
AT (1) ATE555790T1 (fr)
AU (1) AU2006291526B2 (fr)
BR (1) BRPI0615881A2 (fr)
CA (1) CA2621399A1 (fr)
EC (1) ECSP088259A (fr)
GT (1) GT200600411A (fr)
IL (1) IL189984A0 (fr)
MA (1) MA29788B1 (fr)
MY (1) MY145751A (fr)
NO (1) NO20081807L (fr)
NZ (1) NZ566474A (fr)
PE (1) PE20070457A1 (fr)
RU (1) RU2424804C2 (fr)
SA (1) SA06270315B1 (fr)
SG (1) SG165371A1 (fr)
TN (1) TNSN08112A1 (fr)
TW (1) TWI325321B (fr)
WO (1) WO2007031265A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605120D0 (en) * 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
WO2008125691A2 (fr) 2007-04-17 2008-10-23 Novartis Ag Composés organiques
JP2010536872A (ja) * 2007-08-22 2010-12-02 アラーガン、インコーポレイテッド 治療用キノリンおよびナフタレン誘導体
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
CA2824028A1 (fr) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Nouvelles urees pour le traitement et la prevention du cancer
JP6104173B2 (ja) * 2011-12-01 2017-03-29 帝國製薬株式会社 ロピニロール含有貼付剤
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CN107245071A (zh) * 2013-04-09 2017-10-13 广州慧柏瑞生物医药科技有限公司 抗新生血管的化合物、其中间体及其用途
EP3064489A4 (fr) * 2013-11-01 2017-06-21 Ube Industries, Ltd. Composé aryloyl(oxy ou amino)pentafluorosulfanylbenzène, sel pharmaceutiquement acceptable de ce composé et promédicaments de celui-ci
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN104860885B (zh) 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
SI3464266T1 (sl) 2016-06-01 2021-12-31 Bayer Animal Health Gmbh Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
US12605375B2 (en) 2020-02-28 2026-04-21 Shanghai Runshi Medical Technology Co., Ltd Use of CSF-1R kinase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
WO2001016130A1 (fr) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Indolinones substituees utilisees comme inhibiteurs de la tyrosine kinase
PL201222B1 (pl) * 2000-06-01 2009-03-31 Watson Pharmaceuticals Preparat transdermalny lazoksyfenu, urządzenie do podawania lazoksyfenu, oraz zastosowanie lazoksyfenu
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US20040265362A1 (en) * 2001-09-04 2004-12-30 Rudy Susilo Plaster for the treatment of dysfunctions and disorders of nail growth
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
US20060004029A1 (en) * 2002-08-30 2006-01-05 Akihiko Tsuruoka Nitrogen-containing aromatic derivatives
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
EP1660503A1 (fr) * 2003-08-29 2006-05-31 Pfizer Inc. Carboxamides de naphtalene et leurs derives utiles comme nouveaux agents anti-angiogeniques
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
WO2005070891A2 (fr) * 2004-01-23 2005-08-04 Amgen Inc Composes et leurs procedes d'utilisation
EP1568368A1 (fr) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Combinaison pharmaceutique comprenant un inhibiteur de CDK et un inhibiteur du recepteur VEGF
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa

Also Published As

Publication number Publication date
AR056194A1 (es) 2007-09-26
ATE555790T1 (de) 2012-05-15
BRPI0615881A2 (pt) 2011-05-31
SG165371A1 (en) 2010-10-28
GT200600411A (es) 2007-05-21
RU2424804C2 (ru) 2011-07-27
WO2007031265A3 (fr) 2007-07-12
EP1945217A2 (fr) 2008-07-23
MY145751A (en) 2012-03-30
RU2008114048A (ru) 2009-10-20
IL189984A0 (en) 2008-11-03
NZ566474A (en) 2011-05-27
US20080306058A1 (en) 2008-12-11
JP2009507871A (ja) 2009-02-26
WO2007031265A2 (fr) 2007-03-22
KR20080058376A (ko) 2008-06-25
AU2006291526A1 (en) 2007-03-22
SA06270315B1 (ar) 2010-12-21
TW200744600A (en) 2007-12-16
CA2621399A1 (fr) 2007-03-22
TWI325321B (en) 2010-06-01
US20120172386A1 (en) 2012-07-05
NO20081807L (no) 2008-05-16
PE20070457A1 (es) 2007-06-06
EP1945217B1 (fr) 2012-05-02
AU2006291526B2 (en) 2010-07-29
ECSP088259A (es) 2008-04-28
TNSN08112A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
MX2007006178A (es) Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular.
MA31907B1 (fr) Nouveaux herbicides
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
WO2009040114A3 (fr) Composés et marqueurs pour diffusion raman exaltée de surface
WO2008014238A3 (fr) Inhibiteurs des iap dimères
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
WO2008005375A3 (fr) Biomarqueurs de la néphrotoxicité
BRPI0605921A2 (pt) compostos orgánicos
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
WO2008112939A3 (fr) Composition et procédé pour préparer des composés oligo-benzamide
MX2010010209A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
MA29816B1 (fr) Composes de benzimidazole thiophene
GB2466912A (en) Compositions and methods for treating lysosomal disorders
TNSN07222A1 (en) Nematicidal compositions
WO2008010162A3 (fr) Ciblage intracellulaire de molécules
WO2008014229A3 (fr) Inhibiteurs des iap dimères
NO20081807L (no) Kombinasjoner innbefattende en VEGF-reseptorinhibitor
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
EA200800713A1 (ru) Аморфные твёрдые дисперсии
FR2897057B1 (fr) Adjuvant pour compositions hydrauliques.
WO2006124630A3 (fr) Compositions et procedes permettant d'augmenter l'efficacite de vaccins
WO2010011684A3 (fr) Promédicament et compositions fluorogéniques et leurs procédés d’utilisation